New approach to stop deadly virus in vulnerable transplant patients

This study tested whether a special antibody treatment (Cytotect®CP) could safely prevent dangerous cytomegalovirus (CMV) infections in patients who had received a stem cell transplant and developed graft-versus-host disease (GVHD). The trial focused on patients at very high risk for CMV because they needed strong steroid treatment for their GVHD. Researchers wanted to see if this antibody approach could prevent infections without the severe side effects common with standard antiviral drugs.